Cartesian Therapeutics, Inc.

NasdaqGM:RNAC Stock Report

Market Cap: US$489.3m

Cartesian Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Carsten Brunn

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.1%
CEO tenure6yrs
CEO ownership0.03%
Management average tenure1.1yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Cartesian Therapeutics: Uncertainty Remains

Nov 10

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 17

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 02

CEO Compensation Analysis

How has Carsten Brunn's remuneration changed compared to Cartesian Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$282m

Jun 30 2024n/an/a

-US$267m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$618k

-US$257m

Compensation vs Market: Carsten's total compensation ($USD6.11M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Insufficient data to compare Carsten's compensation with company performance.


CEO

Carsten Brunn (53 yo)

6yrs

Tenure

US$6,111,883

Compensation

Dr. Carsten Brunn, Ph.D. serves as President, Chief Executive Officer & Director of Cartesian Therapeutics, Inc. since December 2018. He served as an Independent Director at Surface Oncology, Inc. since Ju...


Leadership Team

NamePositionTenureCompensationOwnership
Carsten Brunn
President6yrsUS$6.11m0.034%
$ 166.1k
Blaine Davis
Chief Financial Officer2.1yrsUS$2.49mno data
Metin Kurtoglu
Chief Technology Officerless than a yearUS$398.28k0.20%
$ 970.7k
Chris Jewell
Chief Scientific Officer1.1yrsUS$296.85k0.054%
$ 266.3k
Matthew Bartholomae
General Counsel & Secretaryno datano datano data
Milos Miljkovic
Chief Medical Officer1.1yrsno data0.071%
$ 347.5k
Emily English
SVP & Head of Manufacturingless than a yearno data0%
$ 0

1.1yrs

Average Tenure

44.5yo

Average Age

Experienced Management: RNAC's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Carsten Brunn
President6yrsUS$6.11m0.034%
$ 166.1k
Carrie Cox
Independent Chairman of the Board5.1yrsUS$292.32k0.028%
$ 134.9k
Timothy Barabe
Independent Director8.4yrsUS$212.93k0.062%
$ 301.2k
Patrick Zenner
Independent Director7.5yrsUS$192.05k0.0072%
$ 35.0k
Timothy Springer
Director8.5yrsUS$192.73k36.19%
$ 177.1m
Nishan DeSilva
Independent Director3.5yrsUS$188.58k0.00091%
$ 4.5k
Kemal Malik
Independent Directorless than a yearno data0%
$ 0
Murat Kalayoglu
Independent Director1.1yrsUS$5.37k19.65%
$ 96.2m
Michael Singer
Independent Director1.1yrsUS$5.71k1.08%
$ 5.3m

5.1yrs

Average Tenure

62yo

Average Age

Experienced Board: RNAC's board of directors are considered experienced (5.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cartesian Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
John NewmanCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.